BrainStorm Cell Therapeutics (OTCQB: BCLI) has appointed former FDA associate commissioner, Peter J. Pitts, to its board of directors (BoD), effective immediately.
Mr. Pitts is a globally recognized expert in healthcare policy, regulatory science, and FDA governance. He previously served as associate commissioner at the FDA and as a member of the U.S. Senior Executive Service. Mr. Pitts currently serves as president and co-founder of the Center for Medicine in the Public Interest (CMPI).
“BrainStorm is conducting some of the most important and scientifically rigorous work in neurodegenerative medicine today,” said Mr. Pitts. “The FDA’s Special Protocol Assessment for this Phase 3b trial is unprecedented in ALS and sends a powerful signal that the agency recognizes both the seriousness of the disease and the strength of the trial design.”
Chaim Lebovits, president and CEO of BrainStorm, added, “We are honored to welcome Peter Pitts to the BrainStorm Board at this defining moment for our company and for the ALS community. Peter’s unparalleled regulatory expertise, credibility, and commitment to patients will be invaluable as we initiate the Phase 3b ENDURANCE trial under our Special Protocol Assessment granted by the FDA.”
